Apellis Pharmaceuticals Stock Options
| APLS Stock | USD 19.47 0.57 2.84% |
Apellis Pharmaceuticals' latest option contracts expiring on October 17th 2025 are carrying combined implied volatility of 0.72 with a put-to-call open interest ratio of 0.29 over 51 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on October 17th 2025. The total put volume is at 302, with calls trading at the volume of 339. This yields a 0.89 put-to-call volume ratio.
Open Interest Against October 17th 2025 Option Contracts
Apellis Pharmaceuticals option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Apellis Pharmaceuticals' lending market. For example, when Apellis Pharmaceuticals' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Apellis Pharmaceuticals, he or she must hedge the risk by shorting Apellis Pharmaceuticals stock over its option's life.
2025-10-17
The chart above shows Apellis Pharmaceuticals' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Apellis Pharmaceuticals' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Apellis Pharmaceuticals' option, there is no secondary market available for investors to trade.
Apellis Pharmaceuticals Maximum Pain Price Across 2025-10-17 Option Contracts
Max pain occurs when Apellis Pharmaceuticals' market makers reach a net positive position across all Apellis Pharmaceuticals' options at a strike price where option holders stand to lose the most money. By contrast, Apellis Pharmaceuticals' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Apellis Pharmaceuticals
Analyzing Apellis Pharmaceuticals' in-the-money options over time can help investors to take a profitable long position in Apellis Pharmaceuticals regardless of its overall volatility. This is especially true when Apellis Pharmaceuticals' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Apellis Pharmaceuticals' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Apellis Pharmaceuticals' stock while costing only a fraction of its price.
Apellis Pharmaceuticals In The Money Call Balance
When Apellis Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Apellis Pharmaceuticals stock is said to be in the money. When it comes to buying Apellis Pharmaceuticals' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Apellis Pharmaceuticals are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Apellis Current Options Market Mood
Apellis Pharmaceuticals' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Apellis Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Apellis Pharmaceuticals' options investors are not very successful. Apellis Pharmaceuticals' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Apellis contract
Base on the Rule 16, the options market is currently suggesting that Apellis Pharmaceuticals will have an average daily up or down price movement of about 0.045% per day over the life of the 2025-10-17 option contract. With Apellis Pharmaceuticals trading at USD 19.47, that is roughly USD 0.008761. If you think that the market is fully incorporating Apellis Pharmaceuticals' daily price movement you should consider buying Apellis Pharmaceuticals options at the current volatility level of 0.72%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Purchasing Apellis Pharmaceuticals options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Apellis calls. Remember, the seller must deliver Apellis Pharmaceuticals stock to the call owner when a call is exercised.
Apellis Pharmaceuticals Option Chain
When Apellis Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Apellis Pharmaceuticals stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Apellis Pharmaceuticals' option chain is a display of a range of information that helps investors for ways to trade options on Apellis. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Apellis. It also shows strike prices and maturity days for a Apellis Pharmaceuticals against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | APLS251017C00040000 | 26 | 40.0 | 0.0 - 0.45 | 0.45 | Out |
Call | APLS251017C00036000 | 5 | 36.0 | 0.0 - 0.35 | 0.35 | Out |
Call | APLS251017C00035000 | 0 | 35.0 | 0.0 - 0.4 | 0.4 | |
Call | APLS251017C00034000 | 0 | 34.0 | 0.0 - 0.45 | 0.45 | |
Call | APLS251017C00033000 | 29 | 33.0 | 0.0 - 0.45 | 0.4 | Out |
Call | APLS251017C00032000 | 3 | 32.0 | 0.0 - 0.5 | 0.5 | Out |
Call | APLS251017C00031000 | 59 | 31.0 | 0.0 - 0.5 | 0.43 | Out |
Call | APLS251017C00030000 | 66 | 30.0 | 0.25 - 0.65 | 0.45 | Out |
Call | APLS251017C00029000 | 3 | 29.0 | 0.3 - 0.55 | 0.73 | Out |
Call | APLS251017C00028000 | 37 | 28.0 | 0.4 - 0.9 | 0.8 | Out |
Call | APLS251017C00027000 | 10 | 27.0 | 0.45 - 0.75 | 0.45 | Out |
Call | APLS251017C00026000 | 6 | 26.0 | 0.65 - 1.15 | 0.9 | Out |
Call | APLS251017C00025000 | 176 | 25.0 | 0.75 - 1.15 | 1.07 | Out |
Call | APLS251017C00024000 | 141 | 24.0 | 1.0 - 1.25 | 1.55 | Out |
Call | APLS251017C00023000 | 77 | 23.0 | 1.25 - 1.5 | 2.04 | Out |
Call | APLS251017C00022000 | 48 | 22.0 | 1.55 - 2.05 | 2.15 | Out |
Call | APLS251017C00021000 | 42 | 21.0 | 1.9 - 2.25 | 2.95 | Out |
Call | APLS251017C00020000 | 3388 | 20.0 | 2.3 - 2.65 | 2.49 | Out |
Call | APLS251017C00019000 | 451 | 19.0 | 2.85 - 3.1 | 2.9 | In |
Call | APLS251017C00018000 | 73 | 18.0 | 3.2 - 3.6 | 3.8 | In |
Call | APLS251017C00017000 | 17 | 17.0 | 3.8 - 4.2 | 3.0 | In |
Call | APLS251017C00014000 | 4 | 14.0 | 5.9 - 6.5 | 5.9 | In |
Call | APLS251017C00013000 | 3 | 13.0 | 6.5 - 7.5 | 7.0 | In |
Call | APLS251017C00011000 | 60 | 11.0 | 8.2 - 9.1 | 8.91 | In |
Call | APLS251017C00010000 | 10 | 10.0 | 9.2 - 11.0 | 7.64 | In |
Put | APLS251017P00040000 | 0 | 40.0 | 20.0 - 21.1 | 20.0 | In |
Put | APLS251017P00036000 | 0 | 36.0 | 16.2 - 17.1 | 16.2 | In |
Put | APLS251017P00035000 | 0 | 35.0 | 15.0 - 16.2 | 15.0 | In |
Put | APLS251017P00034000 | 0 | 34.0 | 14.4 - 15.0 | 14.4 | In |
Put | APLS251017P00033000 | 0 | 33.0 | 13.1 - 13.9 | 13.1 | In |
Put | APLS251017P00032000 | 0 | 32.0 | 12.3 - 13.2 | 12.3 | In |
Put | APLS251017P00031000 | 0 | 31.0 | 11.4 - 12.3 | 11.4 | In |
Put | APLS251017P00030000 | 0 | 30.0 | 10.4 - 11.2 | 10.4 | In |
Put | APLS251017P00029000 | 0 | 29.0 | 9.4 - 10.5 | 9.4 | In |
Put | APLS251017P00028000 | 0 | 28.0 | 8.5 - 9.3 | 8.5 | In |
Put | APLS251017P00027000 | 3 | 27.0 | 7.7 - 8.6 | 7.7 | In |
Put | APLS251017P00026000 | 4 | 26.0 | 6.9 - 7.3 | 6.9 | In |
Put | APLS251017P00025000 | 65 | 25.0 | 6.1 - 6.6 | 6.1 | In |
Put | APLS251017P00024000 | 2 | 24.0 | 5.3 - 6.0 | 5.3 | In |
Put | APLS251017P00023000 | 2 | 23.0 | 4.5 - 5.3 | 4.5 | In |
Put | APLS251017P00022000 | 54 | 22.0 | 3.8 - 4.6 | 4.73 | In |
Put | APLS251017P00021000 | 15 | 21.0 | 3.2 - 3.8 | 3.2 | In |
Put | APLS251017P00020000 | 30 | 20.0 | 2.6 - 2.95 | 2.6 | In |
Put | APLS251017P00019000 | 273 | 19.0 | 2.1 - 2.65 | 2.3 | Out |
Put | APLS251017P00018000 | 101 | 18.0 | 1.6 - 1.95 | 1.85 | Out |
Put | APLS251017P00017000 | 13 | 17.0 | 1.1 - 1.4 | 1.35 | Out |
Put | APLS251017P00016000 | 4 | 16.0 | 0.8 - 1.1 | 0.8 | Out |
Put | APLS251017P00015000 | 593 | 15.0 | 0.6 - 0.8 | 0.65 | Out |
Put | APLS251017P00014000 | 112 | 14.0 | 0.35 - 0.7 | 0.8 | Out |
Put | APLS251017P00013000 | 17 | 13.0 | 0.2 - 0.5 | 0.2 | Out |
Put | APLS251017P00012000 | 96 | 12.0 | 0.0 - 0.35 | 0.55 | Out |
Apellis Total Stockholder Equity
Total Stockholder Equity |
|
Apellis Pharmaceuticals Corporate Management
| James CPA | Corporate VP | Profile | |
| Cedric MD | President, CoFounder | Profile | |
| Adam Townsend | Chief Commercial Officer | Profile | |
| Philip MD | Chief Advisor | Profile | |
| Karen Lewis | Chief Officer | Profile |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.